{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:54:28Z","timestamp":1787241268959,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Eflornithine is a recommended treatment against late-stage\n                    <jats:italic>gambiense<\/jats:italic>\n                    human African trypanosomiasis, a neglected tropical disease. Standard dosing of eflornithine consists of repeated intravenous infusions of a racemic mixture of L- and D-eflornithine. Data from three clinical studies, (i) eflornithine intravenous monotherapy, (ii) nifurtimox-eflornithine combination therapy, and (iii) eflornithine oral monotherapy, were pooled and analyzed using a time-to-event pharmacodynamic modeling approach, supported by\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity data of the individual enantiomers. Our aim was to assess (i) the efficacy of the eflornithine regimens in a time-to-event analysis and (ii) the feasibility of an L-eflornithine-based therapy integrating clinical and preclinical data. A pharmacodynamic time-to-event model was used to estimate the total dose of eflornithine, associated with 50% reduction in baseline hazard, when administered as monotherapy or in the nifurtimox-eflornithine combination therapy. The estimated total doses were 159, 60 and 291 g for intravenous eflornithine monotherapy, nifurtimox-eflornithine combination therapy and oral eflornithine monotherapy, respectively. Simulations suggested that L-eflornithine achieves a higher predicted median survival, compared to when racemate is administered, as treatment against late-stage\n                    <jats:italic>gambiense<\/jats:italic>\n                    human African trypanosomiasis. Our findings showed that oral L-eflornithine-based monotherapy would not result in adequate efficacy, even at high dose, and warrants further investigations to assess the potential of oral L-eflornithine-based treatment in combination with other treatments such as nifurtimox. An all-oral eflornithine-based regimen would provide easier access to treatment and reduce burden on patients and healthcare systems in\n                    <jats:italic>gambiense<\/jats:italic>\n                    human African trypanosomiasis endemic areas.\n                  <\/jats:p>","DOI":"10.1208\/s12248-022-00693-2","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T19:02:24Z","timestamp":1648234944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy"],"prefix":"10.1208","volume":"24","author":[{"given":"Carl","family":"Amilon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-6226","authenticated-orcid":false,"given":"Mikael","family":"Boberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"\u00c4bel\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Jansson-L\u00f6fmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"693_CR1","unstructured":"WHO. Accelerating Work to overcome the global impact of neglected tropical diseases: A roadmap for implementation. WHO Executive Summary. 2012."},{"issue":"4","key":"693_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1172\/JCI21052","volume":"113","author":"PG Kennedy","year":"2004","unstructured":"Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest. 2004;113(4):496\u2013504. https:\/\/doi.org\/10.1172\/JCI21052.","journal-title":"J Clin Invest"},{"issue":"5","key":"693_CR3","doi-asserted-by":"publisher","first-page":"e0008261","DOI":"10.1371\/journal.pntd.0008261","volume":"14","author":"JR Franco","year":"2020","unstructured":"Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, Simarro PP, Zhao W, Argaw D. Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018. PLoS Negl Trop Dis. 2020;14(5):e0008261. https:\/\/doi.org\/10.1371\/journal.pntd.0008261.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"693_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1212\/01.wnl.0000208221.55385.55","volume":"66","author":"PG Kennedy","year":"2006","unstructured":"Kennedy PG. Human African trypanosomiasis: in and out of Africa. Neurology. 2006;66(7):962\u20133. https:\/\/doi.org\/10.1212\/01.wnl.0000208221.55385.55.","journal-title":"Neurology."},{"issue":"10","key":"693_CR5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/jama.1991.03460100029008","volume":"265","author":"SL Nightingale","year":"1991","unstructured":"Nightingale SL. From the Food and Drug Administration. Jama. 1991;265(10):1229.","journal-title":"Jama."},{"issue":"5","key":"693_CR6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1067\/mjd.2001.117853","volume":"45","author":"PE Coyne Jr","year":"2001","unstructured":"Coyne PE Jr. The eflornithine story. J Am Acad Dermatol. 2001;45(5):784\u20136. https:\/\/doi.org\/10.1067\/mjd.2001.117853.","journal-title":"J Am Acad Dermatol"},{"key":"693_CR7","doi-asserted-by":"crossref","unstructured":"Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science (New York, NY). 1980;210(4467):332-4.","DOI":"10.1126\/science.6775372"},{"key":"693_CR8","unstructured":"WHO. WHO model list of essential medicines, 16th list March 2009. 2009;Available from www.who.int\/medicines\/publications\/essentialmedicines\/en\/, Accessed Jan 7, 2022."},{"issue":"9683","key":"693_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","volume":"374","author":"G Priotto","year":"2009","unstructured":"Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374(9683):56\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(09)61117-X.","journal-title":"Lancet."},{"issue":"2","key":"693_CR10","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1371\/journal.pntd.0000064","volume":"1","author":"F Checchi","year":"2007","unstructured":"Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G. Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis. 2007;1(2):e64. https:\/\/doi.org\/10.1371\/journal.pntd.0000064.","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"693_CR11","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1086\/522982","volume":"45","author":"G Priotto","year":"2007","unstructured":"Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis. 2007;45(11):1435\u201342. https:\/\/doi.org\/10.1086\/522982.","journal-title":"Clin Infect Dis"},{"key":"693_CR12","unstructured":"WHO. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. 2019."},{"issue":"8","key":"693_CR13","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1128\/AAC.00050-08","volume":"52","author":"R Jansson","year":"2008","unstructured":"Jansson R, Malm M, Roth C, Ashton M. Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. Antimicrob Agents Chemother. 2008;52(8):2842\u20138. https:\/\/doi.org\/10.1128\/AAC.00050-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"693_CR14","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1128\/AAC.04101-14","volume":"59","author":"R Jansson-Lofmark","year":"2015","unstructured":"Jansson-Lofmark R, Na-Bangchang K, Bjorkman S, Doua F, Ashton M. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. Antimicrob Agents Chemother. 2015;59(2):1299\u2013307. https:\/\/doi.org\/10.1128\/AAC.04101-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"693_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10928-012-9293-x","volume":"40","author":"CC Johansson","year":"2013","unstructured":"Johansson CC, Gennemark P, Artursson P, Abelo A, Ashton M, Jansson-Lofmark R. Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. J Pharmacokinet Pharmacodyn. 2013;40(1):117\u201328. https:\/\/doi.org\/10.1007\/s10928-012-9293-x.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"693_CR16","doi-asserted-by":"publisher","first-page":"e0009583","DOI":"10.1371\/journal.pntd.0009583","volume":"15","author":"M Boberg","year":"2021","unstructured":"Boberg M, Cal M, Kaiser M, Jansson-Lofmark R, Maser P, Ashton M. Enantiospecific antitrypanosomal in vitro activity of eflornithine. PLoS Negl Trop Dis. 2021;15(7):e0009583. https:\/\/doi.org\/10.1371\/journal.pntd.0009583.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7646","key":"693_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/bmj.39485.592674.BE","volume":"336","author":"G Priotto","year":"2008","unstructured":"Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, Hewison C, Balasegaram M. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ. 2008;336(7646):705\u20138. https:\/\/doi.org\/10.1136\/bmj.39485.592674.BE.","journal-title":"BMJ."},{"key":"693_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/RRTM.S34399","volume":"3","author":"JR Franco","year":"2012","unstructured":"Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Samo M, Jannin JG. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Res Rep Trop Med. 2012;3:93\u2013101. https:\/\/doi.org\/10.2147\/RRTM.S34399.","journal-title":"Res Rep Trop Med"},{"issue":"4","key":"693_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00228-004-0759-7","volume":"60","author":"K Na-Bangchang","year":"2004","unstructured":"Na-Bangchang K, Doua F, Konsil J, Hanpitakpong W, Kamanikom B, Kuzoe F. The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness. Eur J Clin Pharmacol. 2004;60(4):269\u201378. https:\/\/doi.org\/10.1007\/s00228-004-0759-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"693_CR20","volume-title":"NONMEM Users Guide","author":"AJ Boeckmann","year":"1989","unstructured":"Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users Guide. Ellicott City, MD, USA: Icon Development Solutions; 1989-2009."},{"issue":"3","key":"693_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed. 2005;79(3):241\u201357. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Methods Prog Biomed"},{"issue":"1","key":"693_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Prog Biomed. 1999;58(1):51\u201364. https:\/\/doi.org\/10.1016\/s0169-2607(98)00067-4.","journal-title":"Comput Methods Prog Biomed"},{"key":"693_CR23","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50. https:\/\/doi.org\/10.1038\/psp.2013.24.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"693_CR24","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1038\/psp.2013.18","volume":"2","author":"N Holford","year":"2013","unstructured":"Holford N. A time to event tutorial for pharmacometricians. CPT Pharmacometrics Syst Pharmacol. 2013;2:e43. https:\/\/doi.org\/10.1038\/psp.2013.18.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"693_CR25","doi-asserted-by":"publisher","unstructured":"Boberg M. Data on in vitro effects of eflornithine against trypanosoma parasites [Internet]. University of Gothenburg; 2021. Available from: https:\/\/doi.org\/10.5878\/1b50-ab56, Accessed Jan 7, 2022.","DOI":"10.5878\/1b50-ab56"},{"issue":"10","key":"693_CR26","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1158\/1535-7163.MCT-16-0142","volume":"15","author":"JW Yates","year":"2016","unstructured":"Yates JW, Ashton S, Cross D, Mellor MJ, Powell SJ, Ballard P. Irreversible inhibition of egfr: modeling the combined pharmacokinetic-pharmacodynamic relationship of osimertinib and its active metabolite AZ5104. Mol Cancer Ther. 2016;15(10):2378\u201387. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0142.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"693_CR27","first-page":"1067","volume":"289","author":"B Tuk","year":"1999","unstructured":"Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther. 1999;289(2):1067\u201374.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"693_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0001-706X(97)00079-X","volume":"68","author":"B Raz","year":"1997","unstructured":"Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop. 1997;68(2):139\u201347.","journal-title":"Acta Trop"},{"issue":"11","key":"693_CR29","first-page":"1284","volume":"78","author":"J Pepin","year":"2000","unstructured":"Pepin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ. 2000;78(11):1284\u201395.","journal-title":"Bull World Health Organ"},{"issue":"4","key":"693_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/0035-9203(93)90044-Q","volume":"87","author":"F Milord","year":"1993","unstructured":"Milord F, Loko L, Ethier L, Mpia B, Pepin J. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg. 1993;87(4):473\u20137.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"693_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/0035-9203(85)90195-6","volume":"79","author":"S Van Nieuwenhove","year":"1985","unstructured":"Van Nieuwenhove S, Schechter PJ, Declercq J, Bone G, Burke J, Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg. 1985;79(5):692\u20138.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"693_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.1984.2.2.124","volume":"2","author":"MD Abeloff","year":"1984","unstructured":"Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin SB. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis. J Clin Oncol. 1984;2(2):124\u201330. https:\/\/doi.org\/10.1200\/JCO.1984.2.2.124.","journal-title":"J Clin Oncol"},{"issue":"3","key":"693_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4269\/ajtmh.1987.37.525","volume":"37","author":"F Doua","year":"1987","unstructured":"Doua F, Boa FY, Schechter PJ, Miezan TW, Diai D, Sanon SR, et al. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Cote d'Ivoire. Am J Trop Med Hyg. 1987;37(3):525\u201333.","journal-title":"Am J Trop Med Hyg"},{"key":"693_CR34","doi-asserted-by":"publisher","unstructured":"De Koning HP. The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history. Trop Med Infect Dis. 2020;5(1). doi: https:\/\/doi.org\/10.3390\/tropicalmed5010014.","DOI":"10.3390\/tropicalmed5010014"},{"issue":"5","key":"693_CR35","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1371\/journal.pntd.0000720","volume":"4","author":"O Yun","year":"2010","unstructured":"Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2010;4(5):e720. https:\/\/doi.org\/10.1371\/journal.pntd.0000720.","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"693_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0169-4758(96)10055-7","volume":"12","author":"NJ White","year":"1996","unstructured":"White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today. 1996;12(10):399\u2013401. https:\/\/doi.org\/10.1016\/0169-4758(96)10055-7.","journal-title":"Parasitol Today"},{"issue":"10116","key":"693_CR37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","volume":"391","author":"V Mesu","year":"2018","unstructured":"Mesu V, Kalonji WM, Bardonneau C, Mordt OV, Blesson S, Simon F, et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(17)32758-7.","journal-title":"Lancet."},{"key":"693_CR38","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","volume":"20","author":"AK Lindner","year":"2019","unstructured":"Lindner AK, Lejon V, Chappuis F, Seixas J, Kazumba L, Barrett MP, Mwamba E, Erphas O, Akl EA, Villanueva G, Bergman H, Simarro P, Kadima Ebeja A, Priotto G, Franco JR. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infect Dis. 2019;20:e38\u201346. https:\/\/doi.org\/10.1016\/S1473-3099(19)30612-7.","journal-title":"Lancet Infect Dis"},{"key":"693_CR39","doi-asserted-by":"publisher","unstructured":"Dickie EA, Giordani F, Gould MK, Maser P, Burri C, Mottram JC, et al. New drugs for human African Trypanosomiasis: a twenty first century success story. Trop Med Infect Dis. 2020;5(1). https:\/\/doi.org\/10.3390\/tropicalmed5010029.","DOI":"10.3390\/tropicalmed5010029"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-022-00693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-022-00693-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-022-00693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T10:04:34Z","timestamp":1653386674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-022-00693-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1208\/s12248-022-00693-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Although co-author C.A. and R.J.L. are employed by AstraZeneca R&D in Gothenburg, Sweden, AstraZeneca had no influence over the study. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"48"}}